The Food and Drug Administration (FDA) announced a significant policy change to publish complete response letters (CRLs) for ongoing drug applications publicly and in real time. This initiative led by FDA Commissioner Marty Makary aims to enhance the credibility and transparency of regulatory decisions. Previously, CRLs were confidential, limiting public insight into agency deliberations regarding drug rejections. The move aligns with broader executive directives for openness in scientific data communication and is expected to improve industry and public trust in FDA assessments.